Hypoxia in cancer malignity. Review.;Hipoxia en la malignidad del cáncer. Revisión

Investigacion Clinica

Volumn 50, Issue 4, 2009, Pages 529-546

  Arvelo, Francisco ^a   Cotte, Carlos ^a  

^a FACULTAD DE CIENCIAS   (Venezuela)

Author keywords

Angiogenesis; Cancer; HIF 1; Hypoxia; Metastasis; Oxigen

Indexed keywords

GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1;

ACIDOSIS; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HYPOXIA; MEDICAL LITERATURE; METASTASIS; NEOPLASM; PROBABILITY; REVIEW; TUMOR GROWTH; TUMOR RECURRENCE;

CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77949737190     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Acker H. The oxygen sensing signal cascade under the influence of reactive oxygen species. Philos Trans R Soc Lond B Biol Sci 2005; 360:2201-2210.
2. Ke Q,Costa M. Hypoxia-inducible factor-1 (HIF-1) Mol Pharmacol 2006; 70: 1469-1480.
3. Semenza GL. Hypoxia, clonal selection, and role of HIF-1 in tumor progressión. Crit Rev Biochem Mol Biol 2000; 35:71-103.
4. Brahimi-Horn C, Pouyssegur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006; 93:E73-E80.
5. Clottes E. Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy. Bull Cancer 2005; 92:119-127.
6. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer metastasis 2007; 26:225-239.
7. Bikfalvi A. Angiogenèse tumorale. Bulletin Cancer 2003; 90:449-458.
8. Conway EM, Colle D, Carmelier P. Molecular mechanism of blood vessel growth. Cardiovas 2001; 49:507-521
9. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8:425-437
10. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 242:1412-1415.
11. Maxwell P, Salnikow K. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol The. 2004; 3:29-35.
12. Michiels C, Minet E, Mottet D, Raes M. Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. Free Radic Biol Med 2002; 33:1231-1242
13. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci USA 1991; 88:5680-5684
14. Harrison LB. Radiotherapy-associated anemia: the scope of the problem. The Oncologist 2000; 5:1-7.
15. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25:43-46.
16. Bus R S. The significance of anemia in clinical radiation therapy. Int. J. Radia Oncol Biol Phys 1986; 12:2047-2050.
17. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor-1 J Biol Chem 1995; 1:1230-1237.
18. Jiang BH, Rue E, Wang GL, Roe R, Semeza GL. Dimerization, DNA binding, and transactivation properties of HIF-1. J Biol Chem 1996; 271:17771-17778.
19. Wang GL, Jiang BH, Rue E, Semenza GL. Hypoxia inducible factor-1 is a Basic-he-lix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92:5510-5514,
20. Salceda S, Caro J. Hypoxia-inducible factor 1 α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J Biol Chem 1997; 272: 22642-22647.
21. Maxwell PH, Wiesener MS, Chang GW. The tumour suppressor protein VHL targets hypoxia inducible factors for oxigendependent proteolysis. Nature 1999; 399: 271-275.
22. Maynard MA, Ohh M. Von Hippel-Lindau tumor supresor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004; 24:1-13.
23. Kaelin WG. Molecular basis of the VHL hereditary cancer síndrome. Nat Rev Cancer 2002; 2:673-682.
24. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor-1 alpha requires multiple posttranslational modifications. Cell Signal 2005; 17: 1-9.
25. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews 2003; 29(Suppl 1):3-9.
26. Hagg M, Wennstrom S. Activation of hypoxia-induced transcription in normoxia. Exp Cell Res 2005; 306:180-191.
27. Lauzier MC, Michaud MD, Dery MA, Richard DE. Activation during tumor progression: implications and consequences. Bulletin Cancer 2006; 93:349-356.
28. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1 alpha by insulin and interleukin-1 beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 2002; 512:157-162.
29. Catrina SB, Botusan IR, Rautanene A, Catrina AI, Pyakurel P, Savu O, Axelson M, Biberfeld P, Poellinger L, Brismark K. Hypoxic-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha are expressed in Kaposi sarcoma and modulated by insulin-like growth factor I. Clin. Cancer Res 2006; 12:4506-4514.
30. Shi YF, Fena CC, Sank Q, Cheunq PY, Tzanq CH, Wu RS, Yana M. Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett 2007; 581(2): 203-210.
31. Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006; 42:167-216.
32. Jones DT, Trowbridge IS, Harris AL. Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res 2006; 66:2749-2756.
33. Lauqsh M, Metzen E, Svensson T, Depping R, Jelkmann W. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008; 122:1005-1011.
34. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115:849-860.
35. Ahn JK, Koh EM, Cha HS, Lee YS, Kim J, Bae EK, Ahn KS. Hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology 2008; 47:834-839.
36. Airley RE, Mobasheri A. Hypoxic regulation of glucosa transport anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007; 53:233-256.
37. Zhu h, Chen XP, Luo SF, Guan J, Sank WG, Sank BX. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 2005; 24:565-574.
38. Ljungberq BJ, Jacobsen J, Rudolfsoon SH, Lindh G, Grankvist K, Rasmuson A. Different vascular endotelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expresión profiles between clear cell and papillary renal cell carcinoma. BJU Int 2006; 98:661-667.
39. Kuhnert F, Tam BY, Sennino B, Gray JT, Yuan J, Jonson A, Kayak NR, Mulligan RC, McDonald DM, Kuo CJ. Soluble receptor-mediated selective inhibition of VEGF-R and PDGF-R beta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA 2008; 105:10185-10190.
40. Lee OH, Xu J, Fueyo J, Alonso MM, Li UD, Martin V, Jianq H, Piao Y, Liu TJ, Gomez-Manzano C. Angiopoietin-2 decreases vascular endothrlial growth factor expresión by modulating HIF-1 alpha levels in gliomas. Oncogene 2008; 27:1310-1314.
41. Eickelberg O, Seebach F, Riordan M, Thulin G, Mann A, Reidy KH, Van Why SK, Kashgarian M, Siegel N. Functional activation of heat shock factor and hypoxia-inducible factor in the kidney. J Am Soc Nephrol 2002; 13:2094-2101.
42. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002; 62: 2478-2482.
43. Cai Z, Manalo DJ, Wei G, Rodríguez ER, Fox-Talbot K, Lu H. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemiareperfusion injury. Circulation 2003; 108: 79-85.
44. Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol 2004; 30:465-468.
45. Kanno H, Kondo K, Ito S, Yamamoto I Fujii S, Torigoe S. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994; 54: 4845-4847.
46. Gnarra JR, Tory K, Weng Y,Schmidt L, Wei MH, Li H, Latif F. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90.
47. Wellmann S, Guschmann M, Griethe W, Eckert C, von Stackelberg A, Lottaz C. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004; 18:926-933.
48. Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004; 5:405-406.
49. Warren BA. Tumor Blood Circulation: Angiogenesis, vascular morphology and blood flow of experimental and human tumors. 1-48 ed. Peterson, H. I. 1979, CRC Press, Boca Raton, USA.
50. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
51. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 94:209-231.
52. Hueyonq L, Shaozonq C, Wanqzhou L, Yuejun L, Xiaoxinq L, Jinq L, Yanli W, Jinqinq L. Differentiation of the pericyte in wound healing: the precursor, the process, and the role of the vascular endotelial cell. Wound Repair Regen 2008; 16: 346-355.
53. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005; 218:1-14.
54. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD. Activation of vascular endotelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16:4604-4613.
55. Hanahan D, Folkman J. Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
56. Conway EM, Collen D, Carmeliet P. Molecular mechanism of blood vessel growth. Cardiovasc Res 2001; 49:507-521.
57. Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endotelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy Curr Med Chem 2004; 11:731-745.
58. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (Suppl 3):4-10.
59. Rosen LS. Clinical experince with angiogenesis signaling inhibitors: focus on vascular endotelial growth factor (VEGF) blockers. Cancer Control 2002; 9:36-44.
60. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endotelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995; 146:1029-1039.
61. Kalas W, Yu JL, Milsom C. Oncogenes and angiogenesis: down-regulation of thrombospondin-1 in normal fibroblast exponed to factors from cancer cells har boring mutant ras. Cancer Res 2005; 65: 8878-8886.
62. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, antiangiogenesis and vascular targeting. Trends Pharmacol 2002; 23:576-582.
63. Hirakawa S, Hong YK, Harvey N. Identification vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endotelial cells. Am J Pathol 2003; 162:575-586.
64. Wissmann C, Detmar M. Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 2006; 12:6865-6868.
65. Da MX, Wu Z, Tian HW. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008; 39:365-372.
66. Chang LK, García-Cardena G, Farnebo F. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci USA 2004; 101:11658-11663.
67. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006; 66: 2650-2657.
68. Stupack DG. The Biology of integrins. Oncology 2007; 9(Suppl 3):6-12.
69. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in Angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008; 8:604-617.
70. Stupak DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004; 64: 207-238.
71. Handsley MM, Edwards DR. Metallo proteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115:849-860.
72. Citak EC, Oquz A, Karadeniz C, Akyurek N. Role gelatinases (MMP-2 and MMP-9), TIMP-1 vascular endotelial growth factor (VEGF), and microvessel density on the clinicophaological behavior of childhood non-Hodgkin Lymphoma. Pediatr Hematol Oncol 2008; 25:55-66.
73. Du R, Lu KV, Petritch C, Liu P, Gauss R, Passequé E, Song H, Vandenberq S, Jonson RS, Werb Z, Bergers G. HIF1 alpha induces the requeriment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13(3):206-220.
74. Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacin A, Castells A, Piqué JM, Volant A, Metges JP. Positive VEGF immunostaining independently predicts poor prognosis in curatively recected gastric cancer patients: results of a study assesing a panel of angiogenic markers. J Gastrointest. Surg 2008; 12:1005-1014.
75. a ed. Lippincott Company, 1993. Philadelphia
76. Arvelo F, Poupon MF. Aspectos Moleculares y Celulares de la Metástasis Cancerosa. Acta Cient Venez 2001; 52:304-312.
77. Langley RR, Fidler I. Tumor cell-organ microenvironment interactions in the patogénesis of cancer metastasis. Endocr Rev 2007; 28:297-321.
78. Xu Y. Induction of genetic instability by gain of function p53 cancer mutants. Oncogene 2008; 27:3501-3507.
79. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049.
80. Sullivan R, Grahan CH. Hypoxia-driven delection of the metastatic phenotype. Cancer Metastasis Rev 2007; 26:319-331.
81. Kim W, Kaelin W. Role of VHL gene mutation in human cancer, J Clin Oncol 2004; 22:4991-5004.
82. Chiang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL, Sun GH. Tumor derived tumor necrosis factor- alpha promote progressión and epithelialmesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008; 99:905-913.
83. He Z, Liu S, Guo M, Mao J, Hughson MD. Expression of fibronectin and HIF-1 alpha in renal cell carcinomas: relationship to von hippel-lindau gene activation. Cancer Genet Cytogenet 2004; 152:89-94.
84. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA, Strieter RM Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006; 5:56-63.
85. Miyazaki Y, Hara A, Kato K, Oyama T, Yamada Y, Mori H, Shibata T. The effect of hypoxic microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell carcinoma. Int J Oncol 2008; 32:145-151.
86. Luo Y, He DL, Ning L,Shen SL, Li L, Li X, Zhan HE, Chug LW. Over-expression of hypoxia-inducible factor-1 alpha increases the invasive potency of LNCaP cells in vitro. BJU Int 2006; 98:1315-1319.
87. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelialmesenchymal transition in hypoxic breast cancer cell. J Cell Biol 2007; 178:425-436.
88. Wanq X, Li C, Chen Y, Hao Y, Zhou W, Chen C, Yu Z. Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1 alpha activation. Biochem. Biophys Res Commun 2008; 37(12):283-288.
89. Kitayima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expressión under hypoxia activates the hepatocyte growth factor/ c-Met system via hypoxia factor-1 in pancreatic cancer. Cancer Sci 2008; 99:1341-1347.
90. Naz C, Hill R. Hypoxia and Metastasis. Clin Cancer Res 2007; 13: 1947-1949.
91. Das S, Skobe M. Lymphatic vessel activation in cancer. Ann NY Acad Sci 2008; 1131:235-241.
92. Subarsky P, Hill RP. The hypoxic tumor microenviroment and metastatic progression. Clin Exp Metastasis 2003; 20:237-250.
93. Hemler ME. Integrin associated proteins. Curr Opin Cell Biol 1998; 10:578-585.
94. Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995; 7: 619-627.
95. Perl K, Wilgenbus P, DahlU, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392:190-193.
96. Pérez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA, Cano A. A new role for E12/E47 in the repression of E-cadherin expresión and epithelial-mesenchymal transitions. J Biol Chem 2001; 276:27424-27431.
97. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis a look outside the nucleus. Science 2000; 287: 1606-1609.
98. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392:190-193.
99. Birchmeier C, Birchmeier W, Brand-Saberi B. Epithelial-mesenchymal transitions in cancer progression. Acta Anat 1996; 156:217-226.
100. Giehl K, Menke A. Microenvironmental regulation of cadherin-mediated adherens junctions. Front Biosci 2008; 13:3975-3985.
101. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, Raval R, O'brien TS, Maxwell PH. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006; 66: 3567-3575.
102. Olmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, Cano A. SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res 2007; 67:11721-11731.
103. Batlle E, Sancho E, Franci C, Domínguez D, Monfar M, Baulida J, García-Herreros A. The transcription factor snail is a represor of E-cadherin gene expression in epithelial tumor cells. Nat Cell Biol 2000; 2:84-89.
104. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A, Portillo R. A molecular role for Lysyl oxidase-like 2 enzyme in Snail regulation and tumor progression. The EMBO Journal 2005; 24: 3446-3458.
105. Manalo D, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SO, Garcia JG, Semenza GL. Transcriptional regulation of vascular endotelial cell responses to hypoxia by HIF1. Blood 2005; 105:659-669.
106. Erler JT, Bennewith KL, Nicilau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222-1226.
107. Shan B, Yao TP, Nguyen HT. Requirement of HDAC6 for TGF-beta1 induced epithelial-mesenchymal transition. J Biol Chem 2008; 283:21065-21073.
108. Choi J, Park SY, Joo CK. Transforming growth factor-beta 1 represses E-cadherin production via slug expresión in lens epithelial cells. Invest Ophthalmol Vis Sci 2007; 48:2708-2718.
109. Jethwa P, Naqui M, Hardy RG. Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol 2008; 14: 1044-1052.
110. Yanaq MH, Wu MZ. Direct regulation of Twist by HIF-1 alpha promotes metastasis. Nat Cell Biol 2008; 10:295-305.
111. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinber RA. Loss of Ecadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645-3654.
112. Medema RH, Bos JL. The role of p21-ras in receptor tyrosine kinase signaling. Crit Rev Oncog 1993; 4:615-661.
113. Wu M, Wu ZF, Merajver SD. Rho proteins and cell-matrix interactions in cancer. Cells Tissues Organs 2007; 185:100-103.
114. Parise LV, Lee J, Juliano RL. New aspects of integrin signaling in cancer. Semin Cancer Biol 2000; 10:407-414.